Member Info for Moneymunch

Yesterday's close provided a new support level for the next move North, and i dare say a few were betting short, or had sold because they were expecting a significant drop as witnessed on the last two spikes ( shorts now closing ha ha ha ha ) , the new support level suggests UPward momentum from now on in....Gla ;-)

Those betting short are in trouble ho ho ho ....Gla...On and UP!!! ;-)

Lol...those that are obviously betting short on the latest rise have called this wrong and are now in trouble......they better bite the bullet or it will cost them dearly.....UPward momentum from now on in imho, and a sudden and significant re-rate with news expected very soon. Gla Holders...On and UP!!! l ;-)

A BIG blue day ahead imho.....watch this space!!! Gla ;-)

Initial trial data from Regeneron/Sanofi's IL-6 inhibitor Kevzara expected soon, Roche's IL-6 Actemra trial data, no doubt will quickly follow, and so given TILS IL-6 inhibitor TZLS-501 with its dual mechanism with reported distinct advantages over both, positive trial data will greatly increase interest in TZLS-501 and potentially add significant value. Gla Holders.....News from TILS on TZLS-501's development could drop at any time. ;-)

Data for Regeneron arthritis drug in coronavirus could come in weeks

April 9, 2020

Regeneron could release data within weeks about how well its arthritis drug Kevzara is battling the new coronavirus, its chief scientific officer said during a STAT video chat Wednesday.

The FDA encouraged Regeneron to embrace a study design that would test the drug in a two-step process without stopping. The first part of the study, due to end soon, will look to see if there is any benefit and to figure out how to measure it. Then, the ongoing study could be used to double check that the effect is actually there, based on the measures that appear potent in the first study phase. That first stage is what could finish soon.

“We are probably a couple weeks or a month away from getting a controlled data answer to really understand whether this shot really makes a difference in a controlled way in patients,” Yancopoulos said. “And I think we all need to know, because we’re all so desperate. We want these things to work.”

https://www.statnews.com/2020/04/09/data-regeneron-arthritis-drug-coronavirus-coming/

TILS finances and funding all in place, $10m plus cash in the bank and an additional $20m war chest, if and when required, a progress UPdate on their IL-Inhibitor TZLS501 could drop at anytime and provide significant UPside, taking the sp up to new highs on positive data. ......the current bargain low will soon be history......Fill Ya Boots!!!Gla ;-)

Tiziana Life Sciences upbeat on potential for coronavirus treatment
Snapshot

TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.

Tiziana Life Sciences - Tiziana Life Sciences upbeat on potential for coronavirus treatment

US and UK listed biotech with three key monoclonal antibody treatments

Has applied for a patent for possible coronavirus treatment

Other products target liver cancer and autoimmune diseases

How it is doing

Shares have soared recently on the potential for Tiziana’s (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications.

TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.

On-the-ground testing in China has revealed anti-IL6R mAbs, currently approved for rheumatoid arthritis, has a role to play in treating patients.

So, the country’s National Health Commission has recommended the use of Roche blockbuster, Actemra, for patients infected with COVID-19 with serious lung damage and elevated IL-6 levels.

Other drugs in development

TZLS-501 is the current focus though last year Tiziana received top-line data from a phase IIa trial of its liver cancer treatment Milciclib as a monotherapy.

A phase 1 trial of its anti-CD3 monoclonal antibody Foralumab delivered via a nasal spray also finished in January with no safety indications and the autoimmune drug being well-tolerated.

Chairman Gabriele Cerrone has high hopes for its nasal delivery method as all autoimmune drugs currently are administered by injection.

What the boss says: Gabriele Cerrone, chairman

“The drug [TZLS-501] works not by treating the virus but attacking inflammation in the lungs - it is attacking the two proteins causing this inflammation.

As such, the chances that we will work against another future strain are very high.

“The technology, we think, provides immediate relief thanks to the delivery speed”

Video

https://www.proactiveinvestors.co.uk/companies/news/917056/tiziana-life-sciences-upbeat-on-potential-for-coronavirus-treatment-917056.html

Lol ..the 3p is the nominal value of all of TILS shares in issue, and have no relevance to current sp....Gla ;-)

8. AIM Securities in Issue

The Company's issued share capital comprises 153,321,181 ordinary shares of nominal value at 3p each.
The percentage of securities not in public hands is 58.01%.
The Company has granted options over a total of 16,584,403 ordinary shares of which 5,326,250 are vested at exercise prices between 15p and £1.86p per share and 11,258,153 remain subject to vesting conditions (at potential exercise prices ranging from 82p to £1.595 per share). In addition warrants to subscribe for a total of 5,093,227 ordinary shares at exercise prices between 42p and £2.50 are outstanding.
There are no restrictions on the transfer of securities.

9. Significant Shareholders
Planwise Group LTD
63,680,404
41.53%*
The Bank of New York (Nominees)
32,558,762
21.24%
Guaranty Nominees Limited
31,210,035
20.36%
Securities Services Nominees
4,946,568
3.23%
Lynchwood Nominees Limited
4,684,461
3.06%
*Gabriele Cerrone, Executive Chairman, is considered to have a beneficial interest in the shares and voting rights held Planwise Group Limited and Panetta Partners Limited, giving him an aggregate interest in share and voting rights equal to 41.99%

5m 13 secs into video, he does suggest that TILS could make a move North and catch the shorters out, and so not total nonsense imho. Gl ;-)

Share Talk Bulletin Board Heroes, Tuesday 14th April 2020
abm April 14, 2020

80p to 90p initially and then on to 1.60p to 1.70p

https://www.share-talk.com/share-talk-bulletin-board-heroes-tuesday-14th-april-2020/

Smokingjoe, MTFB's market cap is £3.2m , NCYT is up 8,500% on testing kits, and so what value for an effective nebulised inhalor treatment for Covid-19 patients, and so imagine if Motif's Iclaprim was used in nebulised inhalor combination , such as Tellamar's technology, and it proved effective for the treatment of severe lung disorders associated with CV, it's already been through Phase 11 patient trials and so can go straight into Covid-19 patient trials without any redtape or delays. It takes 10's of millions to get a drug through phase 11 trials and iclaprim is ready to go......the UPside could conceivably eclipse NCYT's stunning performance. Gla ;-)

ps and still no speeding ticket....and so good news must be coming, surely??? Gla ;-)

Market cap is only £3m yet their lead drug compound has cleared Phase 11 trials which would cost any drug developer 10's of millions to reach, and although the FDA wanted further costly Phase 111 patient trials last February for iclaprim because of toxicity issues, it was being developed for acute bacterial skin and skin structure infections (ABSSSI), but was always believed it could be of benefit for pneumonia lung infections, and now were into thise CV global crisis, where the urgency is to find treatments and a vaccine, MTFB has a drug compound that is believed to be of benefit in nebulise inhalor combination, and is ahead of the game as it is can go straight into phase 111 patient trials, it also in preclinical trials since October with the US Army WRAIR....and the market cap is a lowly £3m...Gla ;-)

Hi noggers. NCYT is up 8,500% since last year on testing kits for Covid-19, and so imagine if Motif's Iclaprim was used in nebulised inhale combination , such as Tellamar's technology, and it proved effective for the treatment of severe lung disorders associated with CV, it's already been through Phase 11 patient trials and so can go straight into Covid-19 patient tials without any redtape or delays, and so maybe just maybe ..Gl ;-)

6/6/19

"We continue to believe that iclaprim has the potential to be an important new treatment option for hospitalised patients with ABSSSI and potentially also in patients with hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia. In addition, we are exploring the use of iclaprim in other disease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.

8/4/20

Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME™ Technology

....................

A LAMELLASOME™ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.

The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in-vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.

Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOME™ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."

hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using

3 positive scenario's for the rise in sp.....news of a RTO, news of sale of Assets ( iclaprim ) or confirmation that Lamellasome formulations, that are believed to be extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients, does infact inlude Iclaprim in combination, and the same combination that WRAIR have in clinical trials since October 2019. Gla ;-)

18/3/20

The Company's Directors remain focused on sourcing an appropriate reverse takeover candidate for Motif Bio and this search continues.

1/5/19

Motif Bio Signs Agreement with Lamellar Biomedical

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.

Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."

Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."

24/10/19

RNS Number: 9200Q Motif Bio PLC, 24 October 2019

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.

https://adisinsi

BOOOOOOOOOOOM!!!! Gla ;-))))

No speeding ticket Rns on Thursday's stellar rise, and so hopefully good news coming. Gl ;-)

In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement. Issuers must also notify without delay information concerning a change in financial condition, performance or expectation of performance if the change would be likely to lead to a substantial share price movement.

There are exclusions from these notification requirements relating to impending developments and matters in the course of negotiation, such as acquisitions or disposals. There is also a power for the UKLA to grant a dispensation from these requirements where the disclosure to the public of information might prejudice the company's legitimate interests

The sp only dropped back at close because the mm's put a UT trade through for 1m at 0.2p at 4.45pm and the Ask remained at 0.29p, and apart from some profit takers, there were plenty of buys coming in towards close at 0.26p, 0.27p and even 0.29p.....and so hard to call which way it will go on Tuesday without news, probably down initially as more punters take profit, but every chance of a quick rebound if there's any substance behind Thursday's stellar rise....and of course if good news does drop, then this could multi-day in a blink from a lowly £1m market cap. Gla holders, excitement building and looking forward to what tomorrow brings. :-)

Building on decades of strategic investments into broad capabilities and a product-oriented research infrastructure, the U.S. Army and WRAIR have been able to consistently maintain a posture of readiness and response to the emerging infectious diseases that threaten U.S. and allied forces.

Our researchers are playing a key role in the ongoing COVID-19 response, building upon the Institute’s ability to rapidly respond to outbreaks on an accelerated timeline to develop diagnostics, vaccines and treatments.

............................

Researching Novel Therapies
WRAIR researchers are also conducting research to identify novel therapies for COVID-19. They are pursuing several drug candidates, similar to the ones WRAIR has successfully developed to treat malaria. In addition, they are conducting studies to identify and characterize monoclonal antibodies (mAbs), a type of immunotherapy. WRAIR has proven experience in this area, having successfully isolated mAbs for other viral pathogens.

https://www.wrair.army.mil/node/318